83 related articles for article (PubMed ID: 20382019)
1. Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.
Ullrich JW; Morris R; Bernotas RC; Travins JM; Jetter J; Unwalla R; Quinet E; Nambi P; Feingold I; Huselton C; Enroth C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 May; 20(9):2903-7. PubMed ID: 20382019
[TBL] [Abstract][Full Text] [Related]
2. 4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.
Bernotas RC; Singhaus RR; Kaufman DH; Travins JM; Ullrich JW; Unwalla R; Quinet E; Evans M; Nambi P; Olland A; Kauppi B; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(1):209-12. PubMed ID: 19932617
[TBL] [Abstract][Full Text] [Related]
3. Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration.
Hu B; Bernotas R; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wilhelmsson A; Nambi P; Evans M; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(2):689-93. PubMed ID: 19962892
[TBL] [Abstract][Full Text] [Related]
4. 4-(3-aryloxyaryl)quinoline alcohols are liver X receptor agonists.
Bernotas RC; Kaufman DH; Singhaus RR; Ullrich J; Unwalla R; Quinet E; Nambi P; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem; 2009 Dec; 17(23):8086-92. PubMed ID: 19853462
[TBL] [Abstract][Full Text] [Related]
5. 1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists.
Travins JM; Bernotas RC; Kaufman DH; Quinet E; Nambi P; Feingold I; Huselton C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(2):526-30. PubMed ID: 20006495
[TBL] [Abstract][Full Text] [Related]
6. 3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists.
Singhaus RR; Bernotas RC; Steffan R; Matelan E; Quinet E; Nambi P; Feingold I; Huselton C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(2):521-5. PubMed ID: 20005711
[TBL] [Abstract][Full Text] [Related]
7. Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist.
Hu B; Unwalla RJ; Goljer I; Jetter JW; Quinet EM; Berrodin TJ; Basso MD; Feingold IB; Nilsson AG; Wilhelmsson A; Evans MJ; Wrobel JE
J Med Chem; 2010 Apr; 53(8):3296-304. PubMed ID: 20350005
[TBL] [Abstract][Full Text] [Related]
8. Biarylether amide quinolines as liver X receptor agonists.
Bernotas RC; Singhaus RR; Kaufman DH; Ullrich J; Fletcher H; Quinet E; Nambi P; Unwalla R; Wilhelmsson A; Goos-Nilsson A; Farnegardh M; Wrobel J
Bioorg Med Chem; 2009 Feb; 17(4):1663-70. PubMed ID: 19162487
[TBL] [Abstract][Full Text] [Related]
9. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.
Kick E; Martin R; Xie Y; Flatt B; Schweiger E; Wang TL; Busch B; Nyman M; Gu XH; Yan G; Wagner B; Nanao M; Nguyen L; Stout T; Plonowski A; Schulman I; Ostrowski J; Kirchgessner T; Wexler R; Mohan R
Bioorg Med Chem Lett; 2015 Jan; 25(2):372-7. PubMed ID: 25435151
[TBL] [Abstract][Full Text] [Related]
10. Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta.
Hu B; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wihelmsson A; Nambi P; Wrobel J
Bioorg Med Chem; 2009 May; 17(10):3519-27. PubMed ID: 19394832
[TBL] [Abstract][Full Text] [Related]
11. Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis.
Hu B; Collini M; Unwalla R; Miller C; Singhaus R; Quinet E; Savio D; Halpern A; Basso M; Keith J; Clerin V; Chen L; Resmini C; Liu QY; Feingold I; Huselton C; Azam F; Farnegardh M; Enroth C; Bonn T; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
J Med Chem; 2006 Oct; 49(21):6151-4. PubMed ID: 17034119
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primates.
Kirchgessner TG; Martin R; Sleph P; Grimm D; Liu X; Lupisella J; Smalley J; Narayanan R; Xie Y; Ostrowski J; Cantor GH; Mohan R; Kick E
J Pharmacol Exp Ther; 2015 Feb; 352(2):305-14. PubMed ID: 25467132
[TBL] [Abstract][Full Text] [Related]
13. Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity.
Hu B; Quinet E; Unwalla R; Collini M; Jetter J; Dooley R; Andraka D; Nogle L; Savio D; Halpern A; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
Bioorg Med Chem Lett; 2008 Jan; 18(1):54-9. PubMed ID: 18023179
[TBL] [Abstract][Full Text] [Related]
14. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
Wrobel J; Steffan R; Bowen SM; Magolda R; Matelan E; Unwalla R; Basso M; Clerin V; Gardell SJ; Nambi P; Quinet E; Reminick JI; Vlasuk GP; Wang S; Feingold I; Huselton C; Bonn T; Farnegardh M; Hansson T; Nilsson AG; Wilhelmsson A; Zamaratski E; Evans MJ
J Med Chem; 2008 Nov; 51(22):7161-8. PubMed ID: 18973288
[TBL] [Abstract][Full Text] [Related]
15. Identification of 5α, 6α-epoxycholesterol as a novel modulator of liver X receptor activity.
Berrodin TJ; Shen Q; Quinet EM; Yudt MR; Freedman LP; Nagpal S
Mol Pharmacol; 2010 Dec; 78(6):1046-58. PubMed ID: 20837678
[TBL] [Abstract][Full Text] [Related]
16. Further modification on phenyl acetic acid based quinolines as liver X receptor modulators.
Hu B; Jetter J; Kaufman D; Singhaus R; Bernotas R; Unwalla R; Quinet E; Savio D; Halpern A; Basso M; Keith J; Clerin V; Chen L; Liu QY; Feingold I; Huselton C; Azam F; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
Bioorg Med Chem; 2007 May; 15(10):3321-33. PubMed ID: 17391964
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist.
Zheng Y; Zhuang L; Fan KY; Tice CM; Zhao W; Dong C; Lotesta SD; Leftheris K; Lindblom PR; Liu Z; Shimada J; Noto PB; Meng S; Hardy A; Howard L; Krosky P; Guo J; Lipinski K; Kandpal G; Bukhtiyarov Y; Zhao Y; Lala D; Van Orden R; Zhou J; Chen G; Wu Z; McKeever BM; McGeehan GM; Gregg RE; Claremon DA; Singh SB
J Med Chem; 2016 Apr; 59(7):3264-71. PubMed ID: 26990539
[TBL] [Abstract][Full Text] [Related]
18. A fragment-based approach for ligand binding affinity and selectivity for the liver X receptor beta.
Salum LB; Andricopulo AD; Honório KM
J Mol Graph Model; 2012 Feb; 32():19-31. PubMed ID: 22030023
[TBL] [Abstract][Full Text] [Related]
19. Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.
Bischoff ED; Daige CL; Petrowski M; Dedman H; Pattison J; Juliano J; Li AC; Schulman IG
J Lipid Res; 2010 May; 51(5):900-6. PubMed ID: 20388921
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRalpha and beta.
Panday N; Benz J; Blum-Kaelin D; Bourgeaux V; Dehmlow H; Hartman P; Kuhn B; Ratni H; Warot X; Wright MB
Bioorg Med Chem Lett; 2006 Oct; 16(19):5231-7. PubMed ID: 16876993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
